ViaCyte Acquisition Can Accelerate Vertex's Ongoing Type 1 Diabetes Programs

Vertex Pharmaceuticals Incorporated  (NASDAQ: VRTX ) has agreed to acquire  ViaCyte , a privately held biotechnology, for $320 million in cash. ViaCyte is focused on delivering stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D). Vertex's VX-880 is an ... Full story available on Benzinga.com